West Michigan Advisors LLC Takes $606,000 Position in Revolution Medicines, Inc. $RVMD

West Michigan Advisors LLC acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,604 shares of the company’s stock, valued at approximately $606,000.

Other hedge funds have also recently made changes to their positions in the company. Indiana Trust & Investment Management Co bought a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $32,000. GAMMA Investing LLC lifted its holdings in shares of Revolution Medicines by 45.1% in the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after purchasing an additional 260 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $40,000. Signaturefd LLC lifted its holdings in shares of Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock valued at $52,000 after purchasing an additional 163 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Revolution Medicines by 51.6% in the fourth quarter. CWM LLC now owns 702 shares of the company’s stock valued at $56,000 after purchasing an additional 239 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock opened at $134.48 on Friday. The business’s fifty day simple moving average is $106.78 and its 200 day simple moving average is $88.60. The firm has a market capitalization of $26.65 billion, a P/E ratio of -22.75 and a beta of 1.01. Revolution Medicines, Inc. has a 12 month low of $34.00 and a 12 month high of $155.70. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same period last year, the company posted ($1.12) earnings per share. As a group, analysts anticipate that Revolution Medicines, Inc. will post -7.57 EPS for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Xiaolin Wang sold 2,010 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares of the company’s stock, valued at $11,545,947.24. This trade represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Jack Anders sold 2,753 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the sale, the chief financial officer directly owned 125,512 shares of the company’s stock, valued at $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 184,592 shares of company stock valued at $24,499,532. Company insiders own 8.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on RVMD shares. Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a report on Monday. HC Wainwright restated a “buy” rating on shares of Revolution Medicines in a report on Wednesday. Benchmark restated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Tuesday. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.